Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Amortizatization of Intangibles (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Amortizatization of Intangibles data on record, last reported at -$3.6 million in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 191.9% year-over-year to -$3.6 million; the TTM value through Dec 2025 reached $961000.0, down 77.19%, while the annual FY2025 figure was $961000.0, 77.19% down from the prior year.
  • Amortizatization of Intangibles reached -$3.6 million in Q4 2025 per TARS's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $4.1 million in Q3 2025 and bottomed at -$3.6 million in Q4 2025.
  • Average Amortizatization of Intangibles over 5 years is $490411.8, with a median of $100000.0 recorded in 2024.
  • Peak YoY movement for Amortizatization of Intangibles: soared 4722.22% in 2023, then plummeted 934.0% in 2025.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$87000.0 in 2021, then rose by 27.59% to -$63000.0 in 2022, then surged by 298.41% to $125000.0 in 2023, then skyrocketed by 3030.4% to $3.9 million in 2024, then tumbled by 191.9% to -$3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were -$3.6 million in Q4 2025, $4.1 million in Q3 2025, and -$834000.0 in Q2 2025.